Inactive Instrument

Other languages Gentian Diagnostics AS Oslo Bors

Equities

NO0010748866

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30
Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors	04-29
Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO	04-29
Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024	03-21
Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024	03-21
Gentian Diagnostics' CEO Resigns, Wins Recommendation to Succeed Chair	03-21
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-09
Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors	12-18
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay	23-09-29
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
Gentian Diagnostics ASA (OB:GENT) acquired Getica Ab from Erling Sundrehagen for SEK 2.8 million.	23-07-02
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Gentian Diagnostics ASA Announces Results from Study on Health Economic Impact of Use of GCAL CalProtectin Immunoassay for Early Detection of Infection in Intensive Care Patients	23-03-22
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16
Gentian Diagnostics ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16
Gentian Diagnostics Asa Announces New Study Addresses the Use of Plasma Calprotectin in Sepsis Management	23-02-15
Gentian Diagnostics ASA Announces Executive Changes, Effective from 1 January 2023	22-12-14
Gentian Diagnostics ASA Receives Patent for NT-proBNP in the U.S	22-12-04
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Gentian Diagnostics AS Oslo Bors

Equities

NO0010748866

Other languages

Filters